Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CCKAR | P32238 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15868599 | 0.91 | HRH4 (0.51) | HRH4MEN1KMT2ADRD3MAPT | |
| SCHEMBL14247344 | 0.89 | KMT2A (0.59) | HRH4MEN1KMT2ADRD3MAPT | |
| SCHEMBL14247798 | 0.86 | HRH4 (0.53) | HRH4MEN1KMT2AMAPTHRH3 | |
| SCHEMBL14247768 | 0.80 | RAB9A (0.60) | MEN1KMT2ADRD3MAPTLMNA | |
| SCHEMBL603687 | 0.80 | HRH4 (0.62) | HRH4KMT2ADRD3HRH3 | |
| SCHEMBL602130 | 0.79 | HRH4 (0.81) | HRH4HRH3 | |
| SCHEMBL602139 | 0.75 | HRH4 (0.60) | HRH4HRH3 | |
| SCHEMBL15868573 | 0.73 | CHEK2 (0.48) | HRH4MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL15861666 | 0.72 | MEN1 (0.43) | HRH4MEN1KMT2ADRD3MAPT | |
| SCHEMBL13175502 | 0.72 | AKR1C3 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194422-A1 | PIPERAZINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-07-10 | — | — | US | claimed |
| WO-2012173952-A1 | PIPERAZINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2012-12-20 | — | — | WO | claimed |
| US-9428478-B2 | Piperazine derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140194422-A1 | PIPERAZINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2012173952-A1 | PIPERAZINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194422-A1 | PIPERAZINE DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | NOX4, NOX5, NOXO1 | HRH4 2893/4885MEN1 4870/4885KMT2A 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.